i-bodies, Human Single Domain Antibodies That Antagonize Chemokine Receptor CXCR4*

CXCR4 is a G protein-coupled receptor with excellent potential as a therapeutic target for a range of clinical conditions, including stem cell mobilization, cancer prognosis and treatment, fibrosis therapy, and HIV infection. We report here the development of a fully human single-domain antibody-like scaffold termed an “i-body,” the engineering of which produces an i-body library possessing a long complementarity determining region binding loop, and the isolation and characterization of a panel of i-bodies with activity against human CXCR4. The CXCR4-specific i-bodies show antagonistic activity in a range of in vitro and in vivo assays, including inhibition of HIV infection, cell migration, and leukocyte recruitment but, importantly, not the mobilization of hematopoietic stem cells. Epitope mapping of the three CXCR4 i-bodies AM3-114, AM4-272, and AM3-523 revealed binding deep in the binding pocket of the receptor.

[1]  A. Cashen.  Plerixafor hydrochloride: a novel agent for the mobilization of peripheral blood stem cells. , 2009, Drugs of today.

[2]  W. Olson,et al.  Anti-CXCR4 Monoclonal Antibodies Recognizing Overlapping Epitopes Differ Significantly in Their Ability To Inhibit Entry of Human Immunodeficiency Virus Type 1 , 2005, Journal of Virology.

[3]  R. Stevens,et al.  Structure-function of the G protein-coupled receptor superfamily. , 2013, Annual review of pharmacology and toxicology.

[4]  P. Hudson,et al.  Construction of recombinant extended single-chain antibody peptide conjugates for use in the diagnosis of HIV-1 and HIV-2. , 1996, Journal of immunological methods.

[5]  H. Ullum,et al.  Longitudinal Analysis of CCR5 and CXCR4 Usage in a Cohort of Antiretroviral Therapy-Naïve Subjects with Progressive HIV-1 Subtype C Infection , 2013, PloS one.

[6]  S. Nuttall.  Overview and discovery of IgNARs and generation of VNARs. , 2012, Methods in molecular biology.

[7]  Piotr Sliz,et al.  Collaboration gets the most out of software , 2013, eLife.

[8]  M. Burdick,et al.  Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. , 2004, The Journal of clinical investigation.

[9]  Andreas Plückthun,et al.  Engineered proteins with desired specificity: DARPins, other alternative scaffolds and bispecific IgGs. , 2014, Current opinion in structural biology.

[10]  Herren Wu,et al.  Molecular basis for the antagonistic activity of an anti-CXCR4 antibody , 2015, mAbs.

[11]  Randy J Read,et al.  Electronic Reprint Biological Crystallography Likelihood-enhanced Fast Rotation Functions Biological Crystallography Likelihood-enhanced Fast Rotation Functions , 2003 .

[12]  Dominique Schols,et al.  Safety, Pharmacokinetics, and Antiviral Activity of AMD3100, a Selective CXCR4 Receptor Inhibitor, in HIV-1 Infection , 2004, Journal of acquired immune deficiency syndromes.

[13]  C. J. Hutchings,et al.  Therapeutic antibodies directed at G protein-coupled receptors , 2010, mAbs.

[14]  Ruben Abagyan,et al.  Crystal structure of the chemokine receptor CXCR4 in complex with a viral chemokine , 2015, Science.

[15]  M. Perugini,et al.  A new robust kinetic assay for DAP epimerase activity. , 2013, Biochimie.

[16]  C. Chothia,et al.  The atomic structure of protein-protein recognition sites. , 1999, Journal of molecular biology.

[17]  Paul E. Kennedy,et al.  HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor , 1996, Science.

[18]  E. De Clercq,et al.  Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100 , 1994, Antimicrobial Agents and Chemotherapy.

[19]  G. Terstappen,et al.  Label-free detection of small-molecule binding to a GPCR in the membrane environment. , 2015, Biochimica et biophysica acta.

[20]  I. D. de Esch,et al.  C(X)CR in silico: Computer-aided prediction of chemokine receptor-ligand interactions. , 2012, Drug discovery today. Technologies.

[21]  M. Flajnik,et al.  Isolation and characterisation of Ebolavirus-specific recombinant antibody fragments from murine and shark immune libraries. , 2011, Molecular immunology.

[22]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[23]  Dominique Schols,et al.  AMD3100, a CxCR4 antagonist, attenuates allergic lung inflammation and airway hyperreactivity. , 2002, The American journal of pathology.

[24]  B. Williams,et al.  Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. , 2005, Blood.

[25]  M. Foley,et al.  Shark IgNAR antibody mimotopes target a murine immunoglobulin through extended CDR3 loop structures , 2008, Proteins.

[26]  R. Wong,et al.  Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4. , 2006, Biochemical pharmacology.

[27]  Arthur J. Rowe,et al.  Analytical ultracentrifugation in biochemistry and polymer science , 1992 .

[28]  R. Ransohoff,et al.  CXCL12 and CXCR4 in bone marrow physiology , 2010, Expert review of hematology.

[29]  B. Wood,et al.  Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. , 2003, Blood.

[30]  A. Otaka,et al.  T140 analogs as CXCR4 antagonists identified as anti‐metastatic agents in the treatment of breast cancer , 2003, FEBS letters.

[31]  M. Rojas,et al.  Role of the SDF-1/CXCR4 axis in the pathogenesis of lung injury and fibrosis. , 2007, American journal of respiratory cell and molecular biology.

[32]  P. Schuck,et al.  Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and lamm equation modeling. , 2000, Biophysical journal.

[33]  J. Varghese,et al.  Structural evidence for evolution of shark Ig new antigen receptor variable domain antibodies from a cell-surface receptor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[34]  R. Leurs,et al.  CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells , 2010, Proceedings of the National Academy of Sciences.

[35]  O. Dolezal,et al.  Kinetic screening of antibody-Im7 conjugates by capture on a colicin E7 DNase domain using optical biosensors. , 2009, Analytical biochemistry.

[36]  E. Buss,et al.  Rapid mobilization of hematopoietic progenitors by AMD3100 and catecholamines is mediated by CXCR4-dependent SDF-1 release from bone marrow stromal cells , 2011, Leukemia.

[37]  B. Williams,et al.  Hemopoietic Stem Cells with Higher Hemopoietic Potential Reside at the Bone Marrow Endosteum , 2007, Stem cells.

[38]  K. Eidne,et al.  Application of G protein-coupled receptor-heteromer identification technology to monitor β-arrestin recruitment to G protein-coupled receptor heteromers. , 2011, Assay and drug development technologies.

[39]  I. Wilson,et al.  Crystal Structure of a Shark Single-Domain Antibody V Region in Complex with Lysozyme , 2004, Science.

[40]  Christie M. Orschell,et al.  Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist , 2005, The Journal of experimental medicine.

[41]  J. Knowles,et al.  Secretion of beta-lactamase into the periplasm of Escherichia coli: evidence for a distinct release step associated with a conformational change. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[42]  A. Zarbock,et al.  Inhibitors of CXC chemokine receptor type 4: putative therapeutic approaches in inflammatory diseases , 2014, Current opinion in hematology.

[43]  M. Foley,et al.  Rapid and precise epitope mapping of monoclonal antibodies against Plasmodium falciparum AMA1 by combined phage display of fragments and random peptides. , 2001, Protein engineering.

[44]  Cheang Ly Be,et al.  Thrombin-cleaved osteopontin regulates hemopoietic stem and progenitor cell functions through interactions with alpha9beta1 and alpha4beta1 integrins. , 2009, Blood.

[45]  Hideo Takahashi,et al.  Structural Basis of the Interaction between Chemokine Stromal Cell-derived Factor-1/CXCL12 and Its G-protein-coupled Receptor CXCR4* , 2009, The Journal of Biological Chemistry.

[46]  T. Kunkel.  Rapid and efficient site-specific mutagenesis without phenotypic selection. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[47]  S. Rasmussen,et al.  Structure of a nanobody-stabilized active state of the β2 adrenoceptor , 2010, Nature.

[48]  B. Williams,et al.  Therapeutic targeting and rapid mobilization of endosteal HSC using a small molecule integrin antagonist , 2016, Nature Communications.

[49]  Guy Georges,et al.  The emerging role of new protein scaffold-based agents for treatment of cancer. , 2013, Cancer genomics & proteomics.

[50]  A. Peled,et al.  CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers , 2009, Leukemia.

[51]  A. Bogan,et al.  Anatomy of hot spots in protein interfaces. , 1998, Journal of molecular biology.

[52]  M. Burdick,et al.  The role of circulating mesenchymal progenitor cells, fibrocytes, in promoting pulmonary fibrosis. , 2009, Transactions of the American Clinical and Climatological Association.

[53]  A. Ben-Baruch,et al.  The chemokine system, and its CCR5 and CXCR4 receptors, as potential targets for personalized therapy in cancer. , 2014, Cancer letters.

[54]  R. Taichman,et al.  G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4 , 2002, Nature Immunology.

[55]  J. Snyder,et al.  Development of a Unique Small Molecule Modulator of CXCR4 , 2012, PloS one.

[56]  A. Korman,et al.  BMS-936564/MDX-1338: A Fully Human Anti-CXCR4 Antibody Induces Apoptosis In Vitro and Shows Antitumor Activity In Vivo in Hematologic Malignancies , 2012, Clinical Cancer Research.

[57]  T. Kenakin.  Functional Selectivity and Biased Receptor Signaling , 2011, Journal of Pharmacology and Experimental Therapeutics.

[58]  Brendan L Wilkinson,et al.  A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations , 2013, Retrovirology.

[59]  M. Vasko,et al.  Models of Inflammation: Carrageenan Air Pouch , 2012, Current protocols in pharmacology.

[60]  D. Herr.  Potential use of G protein-coupled receptor-blocking monoclonal antibodies as therapeutic agents for cancers. , 2012, International review of cell and molecular biology.

[61]  M. Foley,et al.  Shark Variable New Antigen Receptor (VNAR) Single Domain Antibody Fragments: Stability and Diagnostic Applications , 2013 .

[62]  M. Rojas,et al.  Inhibition of the CXCL12/CXCR4-Axis as Preventive Therapy for Radiation-Induced Pulmonary Fibrosis , 2013, PloS one.

[63]  S. Nimmagadda,et al.  The intricate role of CXCR4 in cancer. , 2014, Advances in cancer research.

[64]  Mette M. Rosenkilde,et al.  Molecular Mechanism of AMD3100 Antagonism in the CXCR4 Receptor , 2004, Journal of Biological Chemistry.

[65]  Ido D. Weiss,et al.  Involvement of the CXCL12/CXCR4 pathway in the recovery of skin following burns. , 2006, The Journal of investigative dermatology.

[66]  T. Wurch,et al.  Novel protein scaffolds as emerging therapeutic proteins: from discovery to clinical proof-of-concept. , 2012, Trends in biotechnology.

[67]  E. Goldman,et al.  Thermal stability and refolding capability of shark derived single domain antibodies. , 2014, Molecular immunology.

[68]  O. Dolezal,et al.  Targeting the hepatitis B virus precore antigen with a novel IgNAR single variable domain intrabody. , 2011, Virology.

[69]  M. Rosenkilde,et al.  Biased and G Protein-Independent Signaling of Chemokine Receptors , 2014, Front. Immunol..

[70]  M. Perugini,et al.  Self-association of Human Apolipoprotein E3 and E4 in the Presence and Absence of Phospholipid* , 2000, The Journal of Biological Chemistry.

[71]  K. Maithal,et al.  Production of recombinant antibodies using bacteriophages. , 2014, European journal of microbiology & immunology.

[72]  Adam J Pawson,et al.  Changes to gonadotropin-releasing hormone (GnRH) receptor extracellular loops differentially affect GnRH analog binding and activation: evidence for distinct ligand-stabilized receptor conformations. , 2008, Endocrinology.

[73]  Randy J. Read,et al.  Acta Crystallographica Section D Biological , 2003 .